Literature DB >> 25538249

pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling.

M Jack Borrok1, Yanli Wu1, Nurten Beyaz1, Xiang-Qing Yu2, Vaheh Oganesyan1, William F Dall'Acqua3, Ping Tsui4.   

Abstract

The Fc domain of IgG has been the target of multiple mutational studies aimed at altering the pH-dependent IgG/FcRn interaction to modulate IgG pharmacokinetics. These studies have yielded antibody variants with disparate pharmacokinetic characteristics, ranging from extended in vivo half-life to those exhibiting extremely rapid clearance. To better understand pH-dependent binding parameters that govern these outcomes and limit FcRn-mediated half-life extension, we generated a panel of novel Fc variants with high affinity binding at acidic pH that vary in pH 7.4 affinities and assessed pharmacokinetic outcomes. Pharmacokinetic studies in human FcRn transgenic mice and cynomolgus monkeys showed that multiple variants with increased FcRn affinities at acidic pH exhibited extended serum half-lives relative to the parental IgG. Importantly, the results reveal an underappreciated affinity threshold of neutral pH binding that determines IgG recycling efficiency. Variants with pH 7.4 FcRn affinities below this threshold recycle efficiently and can exhibit increased serum persistence. Increasing neutral pH FcRn affinity beyond this threshold reduced serum persistence by offsetting the benefits of increased pH 6.0 binding. Ultra-high affinity binding to FcRn at both acidic and neutral pH leads to rapid serum clearance.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Antibody Engineering; Fc Receptor; FcRn; Monoclonal Antibody; Phage Display; Pharmacokinetics

Mesh:

Substances:

Year:  2014        PMID: 25538249      PMCID: PMC4326836          DOI: 10.1074/jbc.M114.603712

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding.

Authors:  W L Martin; A P West; L Gan; P J Bjorkman
Journal:  Mol Cell       Date:  2001-04       Impact factor: 17.970

Review 2.  Multiple roles for the major histocompatibility complex class I- related receptor FcRn.

Authors:  V Ghetie; E S Ward
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

3.  High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

Authors:  R L Shields; A K Namenuk; K Hong; Y G Meng; J Rae; J Briggs; D Xie; J Lai; A Stadlen; B Li; J A Fox; L G Presta
Journal:  J Biol Chem       Date:  2000-11-28       Impact factor: 5.157

4.  Engineered human IgG antibodies with longer serum half-lives in primates.

Authors:  Paul R Hinton; Mary G Johlfs; Joanna M Xiong; Kelly Hanestad; Kelly C Ong; Chuck Bullock; Stephen Keller; Meina Tao Tang; J Yun Tso; Max Vásquez; Naoya Tsurushita
Journal:  J Biol Chem       Date:  2003-12-29       Impact factor: 5.157

5.  WebLogo: a sequence logo generator.

Authors:  Gavin E Crooks; Gary Hon; John-Marc Chandonia; Steven E Brenner
Journal:  Genome Res       Date:  2004-06       Impact factor: 9.043

6.  Sequence logos: a new way to display consensus sequences.

Authors:  T D Schneider; R M Stephens
Journal:  Nucleic Acids Res       Date:  1990-10-25       Impact factor: 16.971

7.  The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs.

Authors:  Derry C Roopenian; Gregory J Christianson; Thomas J Sproule; Aaron C Brown; Shreeram Akilesh; Nadja Jung; Stefka Petkova; Lia Avanessian; Eun Young Choi; Daniel J Shaffer; Peter A Eden; Clark L Anderson
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

8.  Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants.

Authors:  M Raghavan; V R Bonagura; S L Morrison; P J Bjorkman
Journal:  Biochemistry       Date:  1995-11-14       Impact factor: 3.162

9.  Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences.

Authors:  William F Dall'Acqua; Robert M Woods; E Sally Ward; Susan R Palaszynski; Nita K Patel; Yambasu A Brewah; Herren Wu; Peter A Kiener; Solomon Langermann
Journal:  J Immunol       Date:  2002-11-01       Impact factor: 5.422

10.  The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan.

Authors:  Chaity Chaudhury; Samina Mehnaz; John M Robinson; William L Hayton; Dennis K Pearl; Derry C Roopenian; Clark L Anderson
Journal:  J Exp Med       Date:  2003-02-03       Impact factor: 14.307

View more
  38 in total

Review 1.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

2.  Enhancement of antibody functions through Fc multiplications.

Authors:  Qun Wang; Yan Chen; Mark Pelletier; Romana Cvitkovic; Jessica Bonnell; Chien-Ying Chang; Adem C Koksal; Ellen O'Connor; Xizhe Gao; Xiang-Qing Yu; Herren Wu; C Kendall Stover; William F Dall'Acqua; Xiaodong Xiao
Journal:  MAbs       Date:  2017-01-19       Impact factor: 5.857

3.  Effects of the FcRn developmental pharmacology on the pharmacokinetics of therapeutic monoclonal IgG antibody in pediatric subjects using minimal physiologically-based pharmacokinetic modelling.

Authors:  Deni Hardiansyah; Chee Meng Ng
Journal:  MAbs       Date:  2018-07-30       Impact factor: 5.857

4.  A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: Effects of Kon, Koff, endosome trafficking, and animal species.

Authors:  Brian M Maas; Yanguang Cao
Journal:  MAbs       Date:  2018-09-11       Impact factor: 5.857

Review 5.  Next generation antibody drugs: pursuit of the 'high-hanging fruit'.

Authors:  Paul J Carter; Greg A Lazar
Journal:  Nat Rev Drug Discov       Date:  2017-12-01       Impact factor: 84.694

6.  Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics.

Authors:  Lindsay B Avery; Jason Wade; Mengmeng Wang; Amy Tam; Amy King; Nicole Piche-Nicholas; Mania S Kavosi; Steve Penn; David Cirelli; Jeffrey C Kurz; Minlei Zhang; Orla Cunningham; Rhys Jones; Brian J Fennell; Barry McDonnell; Paul Sakorafas; James Apgar; William J Finlay; Laura Lin; Laird Bloom; Denise M O'Hara
Journal:  MAbs       Date:  2018-01-29       Impact factor: 5.857

7.  Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies.

Authors:  Lindsay B Avery; Mengmeng Wang; Mania S Kavosi; Alison Joyce; Jeffrey C Kurz; Yao-Yun Fan; Martin E Dowty; Minlei Zhang; Yiqun Zhang; Aili Cheng; Fei Hua; Hannah M Jones; Hendrik Neubert; Robert J Polzer; Denise M O'Hara
Journal:  MAbs       Date:  2016-05-27       Impact factor: 5.857

8.  Conformational Destabilization of Immunoglobulin G Increases the Low pH Binding Affinity with the Neonatal Fc Receptor.

Authors:  Benjamin T Walters; Pernille F Jensen; Vincent Larraillet; Kevin Lin; Thomas Patapoff; Tilman Schlothauer; Kasper D Rand; Jennifer Zhang
Journal:  J Biol Chem       Date:  2015-12-01       Impact factor: 5.157

Review 9.  Targeting FcRn for the modulation of antibody dynamics.

Authors:  E Sally Ward; Siva Charan Devanaboyina; Raimund J Ober
Journal:  Mol Immunol       Date:  2015-03-09       Impact factor: 4.407

Review 10.  Targeting FcRn to Generate Antibody-Based Therapeutics.

Authors:  E Sally Ward; Raimund J Ober
Journal:  Trends Pharmacol Sci       Date:  2018-08-22       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.